Division of Infectious Diseases

#PharmToExamTable: Treatment of Clostridioides difficile infection in adults: What is the evidence supporting a tapered vancomycin regimen?

This is a continuation of this month’s #PharmToExamTable question about C. difficile treatment: What is the evidence supporting a tapered vancomycin regimen?

-Answered by Andre Wilt, PharmD 2020 Graduate of UNMC College of Pharmacy (Reviewed by Scott Bergman PharmD and Andrew Watkins PharmD)

#PharmToExamTable: Treatment of Clostridioides difficile infection in adults: Guideline review

This month’s #PharmToExamTable question was a review of Clostridioides difficile treatment guidelines:
-Answered by Andre Wilt, PharmD 2020 Graduate of UNMC College of Pharmacy (Reviewed by Scott Bergman PharmD and Andrew Watkins PharmD)

The Weekly Corona with Dr. Raquel Lamarche

Dr. Raquel Lamarche is a PGY1 Internal Medicine/Pediatrics resident at UNMC, who will be summarizing updates about SARS-CoV-2 and hopefully make information easier to digest, with additional outlines of implications for graduate medical education.

#PharmToExamTable: What is the evidence for continuous infusion dosing of cefazolin?

The following is a clinical review written by Corey Paz, PharmD. Recent graduate of UNMC College of Pharmacy and new PGY1 Pharmacy Resident at Gunderson Health System in LaCrosse, Wisconsin. Follow him on Twitter @coreypaz. Corey was supervised by Scott Bergman, PharmD, FCCP, FIDSA, BCPS. Pharmacy Coordinator for Antimicrobial Stewardship at Nebraska Medicine and Clinical Associate Professor in the UNMC Dept of Pharmacy Practice and… Continue Reading

Happy National Pharmacy Week!

We LOVE our UNMC ID Pharmacists! This week is National Pharmacy Week and we want to share our appreciation and thanks for the hard work and invaluable contributions of our pharmacists at UNMC ID. Our pharmacists are not only exceptional clinicians giving us the clinical advice we need on antimicrobials and drug interactions, but they are also published national experts in Antimicrobial Stewardship and HIV,… Continue Reading

Bryan Alexander, PharmD on Why I Love ID

Why I love ID: I love academic medicine; working jointly with an interdisciplinary team of experts to sort out the most complex clinical cases excites me. There is no place in the region that fulfills each of the aspects of that statement better than Nebraska Medicine. While more and more of the practice of medicine necessarily moves to the long-term management of chronic disease states,… Continue Reading

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

The following is a clinical review written by Allison Graner, UNMC College of Pharmacy PharmD candidate 2019, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program What is the appropriate treatment for urinary tract infection caused by Candida glabrata? Infections caused by the fungus known as Candida, the most common fungus to be cultured in the microbiology lab… Continue Reading

Are you a Pharmacist interested in an Infectious Diseases Clinical Practice? UNMC ID has the perfect job for you!

The Department of Pharmaceutical and Nutrition Care at Nebraska Medicine and the Division of Infectious Diseases at the University of Nebraska Medical Center (UNMC) are recruiting for a full-time clinical pharmacist to expand the Antimicrobial Stewardship Program and develop an Outpatient Parenteral Antimicrobial Therapy (OPAT) program in collaboration with a new Orthopedic Infectious Diseases service line. This is a unique position that allows a candidate… Continue Reading

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine Currently, triple therapy regimens constituted with a two nucleoside reverse transcriptase inhibitor backbone and anchored by an integrase inhibitor has been the standard treatment for HIV infection. However, these conventional therapies are being challenged due to their long-term side effects. Dual therapy regimens were recently introduced with the first comprising of dolutegravir (DTG)/rilpivirine (RPV)…. Continue Reading

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir alafenamide (1). Current HIV guidelines recommend integrase strand transfer inhibitor… Continue Reading